{
    "table_id": "finqa_84ec0dd4db",
    "source": "finqa",
    "original_metadata": {
        "source_dataset": "finqa",
        "document_id": "LLY/2018/page_42.pdf-1",
        "pre_text_caption_evidence": [
            "financial statement impact we believe that our accruals for sales returns , rebates , and discounts are reasonable and appropriate based on current facts and circumstances .",
            "our global rebate and discount liabilities are included in sales rebates and discounts on our consolidated balance sheet .",
            "our global sales return liability is included in other current liabilities and other noncurrent liabilities on our consolidated balance sheet .",
            "as of december 31 , 2018 , a 5 percent change in our global sales return , rebate , and discount liability would have led to an approximate $ 275 million effect on our income before income taxes .",
            "the portion of our global sales return , rebate , and discount liability resulting from sales of our products in the u.s .",
            "was approximately 90 percent as of december 31 , 2018 and december 31 , 2017 .",
            "the following represents a roll-forward of our most significant u.s .",
            "pharmaceutical sales return , rebate , and discount liability balances , including managed care , medicare , and medicaid: ."
        ],
        "question": "what was the percentage change in u.s . pharmaceutical sales return , rebate , and discount liability balances , including managed care , medicare , and medicaid between 2017 and 2018?"
    },
    "dimensions": {
        "rows": 4,
        "columns": 3
    },
    "schema": {
        "columns": [
            "( dollars in millions )",
            "2018",
            "2017"
        ],
        "dtypes": {
            "( dollars in millions )": "object",
            "2018": "object",
            "2017": "object"
        }
    }
}